pramlintide acetate
Sponsors
AstraZeneca, University of Maryland, Baltimore, McGill University
Conditions
Diabetes Mellitus, Non-Insulin-DependentDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Hyperglycemia, PostprandialObesityOverweightPostprandial HyperglycemiaType 1 Diabetes
Phase 1
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
CompletedNCT01708044
Start: 2012-11-30End: 2013-09-30Updated: 2014-10-20
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
CompletedNCT02500979
Start: 2015-08-17End: 2016-08-05Updated: 2018-11-02
Phase 2
Evaluation of the Bioavailability of Pramlintide
CompletedNCT00042471
Start: 2002-06-30End: 2002-12-31Updated: 2015-09-23
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
CompletedNCT00042601
Start: 2002-07-31End: 2003-10-31Updated: 2015-10-21
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide
CompletedNCT00044707
Start: 2002-08-31End: 2002-09-30Updated: 2015-05-21
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
CompletedNCT00112021
Start: 2005-05-31End: 2005-11-30Updated: 2015-04-10
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
CompletedNCT00189514
Start: 2005-09-30End: 2007-06-30Updated: 2015-06-11
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
CompletedNCT00313183
Start: 2006-04-30End: 2007-08-31Updated: 2015-03-06
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
CompletedNCT00402077
Start: 2006-11-30End: 2007-08-31Updated: 2015-03-06
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
CompletedNCT00444561
Start: 2004-08-31End: 2005-05-31Updated: 2015-06-11
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
CompletedNCT00673387
Start: 2008-04-30End: 2009-10-31Updated: 2015-04-15
Phase 3
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
CompletedNCT00042458
Start: 2002-04-30End: 2003-03-31Updated: 2015-09-23
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
CompletedNCT00107107
Start: 2002-11-30End: 2005-06-30Updated: 2015-09-23
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
CompletedNCT00108004
Start: 2003-04-30End: 2005-06-30Target: 400Updated: 2015-05-21
Phase 4
Unknown Phase
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
CompletedNCT00229658
Start: 2005-09-30End: 2008-05-31Updated: 2015-03-25
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
WithdrawnNCT00732147
Start: 2009-04-30End: 2011-04-30Updated: 2021-07-22
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
CompletedNCT04163874
Start: 2020-02-14End: 2022-01-30Updated: 2022-10-10
Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes
NCT04243629
Start: 2021-11-12End: 2024-04-30Target: 26Updated: 2023-03-15